Early results from the Phase I/II NXTAGE trial show that NXT007 may achieve hemostatic normalization in patients with ...

Roche has demonstrated the power of combining two of oncology's hottest modalities—bispecifics and antibody-drug conjugates ...

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

The pharma group has presented phase 1/2 results with new candidate NXT007 at the International Society on Thrombosis and ...

Insight Foundation has asked a federal judge to dismiss a lawsuit filed by a medical diagnostics company for nearly $300,000.

Shares of Roche drew increased retail attention Monday after the Swiss drugmaker said it would move its investigational ...

The decision to advance prasinezumab to Phase III was based on results from the Phase IIb PADOVA trial, which demonstrated ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.